| 1 | Microwave assisted synthesis of PQ-GDY@NH_(2)-UIO-66(Zr) for improved photocatalytic removal of NOx under visible light显示文摘Pyrazinoquinoxaline-based graphdiyne (PQ-GDY) contains a fixed number of sp-sp2hybridized carbon atoms and pyrazine-like sp2hybridized N atoms.In this paper,NH_(2)-UIO-66(Zr) on PQ-GDY substrate was successfully constructed with the help of microwaveassisted heating.PQ-GDY surface acts as a microwave antenna under microwave irradiation to rapidly absorb microwave energy and form hot spots (hot spot effect),which facilitates the formation of well-dispersed NH2-UIO-66(Zr) with good crystallinity.Transient absorption spectra show that high hole transport property of PQ-GDY can accelerate the migration of photogenerated holes from NH2-UIO-66(Zr) to PQ-GDY and greatly reduce the recombination rate of photogenerated electrons and holes due to the strong interaction between PQ-GDY and NH2-UIO-66(Zr).Under visible light (λ≥420 nm),PQ-GDY@NH_(2)-UIO-66(Zr) shows high photocatalytic stability and high NO_(x)removal rate up to 74%,which is 44% higher than that of primitive NH_(2)-UIO-66(Zr).At the same time,it inhibits the formation of toxic byproducts (NO2) and limits its concentration to a low level. | Qingyu Yang Shuangjun Li Rui Liang Lei Gao Shao Zhang Junfen Jia Yiran Liu Rundong Lyv Guisheng Li Shengxiong Xiao Dieqing Zhang | 2023 | Journal of Environmental Sciences2023，，12： | 0 |
| 2 | Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma显示文摘Rituximab maintenance(RM)prolongs the progression-free survival(PFS)of responding patients with follicular lymphoma(FL),but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index(FLIPI)risk group is still confusing.We performed a retrospective analysis of the effect of RM treatments in patients with FL responding to induction therapy based on their FLIPI risk assessment carried out prior to treatment.We identified 93 patients between 2013 and 2019 who received RM every 3 months for≥4 doses(RM group),and 60 patients who did not accept RM or received rituximab less than 4 doses(control group).After a median follow-up of 39 months,neither median overall survival(OS)nor PFS was reached for the entire population.The PFS was significantly prolonged in the RM group compared to the control group(median PFS NA vs 83.1 months,P=.00027).When the population was divided into the 3 FLIPI risk groups,the PFS differed significantly(4-year PFS rates,97.5%vs 88.8%vs 72.3%,P=.01)according to group.There was no significant difference in PFS for FLIPI low-risk patients with RM compared to the control group(4-year PFS rates,100%vs 93.8%,P=.23).However,the PFS of the RM group was significantly prolonged for FLIPI intermediate-risk(4-year PFS rates,100%vs 70.3%,P=.00077)and high-risk patients(4-year PFS rates,86.7%vs 57.1%,P=.023).These data suggest that standard RM significantly prolongs the PFS of patients assigned to intermediate-and high-risk FLIPI groups but not to low-risk FLIPI group,and pending larger-scale studies to validate. | Ru Li Tingyu Wang Rui Lyv Yi Wang Ying Yu Yuting Yan Qi Sun Wenjie Xiong Wei Liu Weiwei Sui Wenyang Huang Huijun Wang Chengwen Li Jun Wang Dehui Zou Gang An Jianxiang Wang Lugui Qiu Shuhua Yi | 2023 | Blood Science2023，5，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员